CDC Recommends Pfizer's RSV Vaccine for Pregnant Women to Protect Newborns

The U.S. Centers for Disease Control and Prevention (CDC) advisory panel has recommended Pfizer's Abrysvo vaccine for respiratory syncytial virus (RSV) to be given during weeks 32 to 36 of pregnancy, providing additional protection for newborns against the disease. This recommendation follows the approval of nirsevimab, an RSV antibody injection, for infants and young children. RSV is the leading cause of hospitalization among infants, and the CDC encourages parents to discuss with their doctors the options of protecting their children against RSV illness through vaccination during pregnancy or immunization after birth.